Related Experiment Video
Updated: Jun 19, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective
Steven Chun-Min Shih1, Sita Bhella1
1Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto, ON M5G 2M9, Canada.
Abstract:
Multiple myeloma (MM) is an incurable plasma cell malignancy. In the context of the current standard of care therapies in Canada, outcomes among patients with relapsed/refractory multiple myeloma (RRMM), particularly those with triple-class (or more) refractory disease remain poor. Immunotherapies have significantly changed the treatment landscape of MM. Since 2021, two BCMA-targeting CAR T-cell therapy products have been approved for RRMM-namely Idecabtagene vicleucel (Ide-cel) (ABECMA®) and Ciltacabtagene autoleucel (Cilta-cel) (CARVYKTI®), both of which are available in the US and Europe. Although they have shown unprecedented efficacy in RRMM, their clinical and logistical limitations must be acknowledged. MM CAR T-cell therapy is likely to be approved in Canada soon. Therefore, it is timely that we review the latest evidence for commercially available CAR T-cell therapy in multiple myeloma, with a focus on its relevance and impact in the Canadian setting. There will be challenges to access and strategies must be in place to ensure equitable care for all Canadians with MM. Alongside haematologists working in the immune effector cell therapy programs, providers in the community will also play a role in the ongoing monitoring and management of long-term side effects including opportunistic infections and late neurotoxicity.
Insights
CAR T-cell therapy offers new hope for relapsed/refractory multiple myeloma (RRMM) patients in Canada. Reviewing evidence and addressing access challenges is crucial for equitable care.
Area of Science:
- Hematology
- Immunotherapy
- Oncology
Background:
- Multiple myeloma (MM) is an incurable plasma cell cancer with poor outcomes for relapsed/refractory (RRMM) patients in Canada.
- Current standard therapies offer limited success for patients with triple-class refractory disease.
Purpose of the Study:
- To review the latest evidence on commercially available CAR T-cell therapies for RRMM.
- To assess the relevance and impact of these therapies in the Canadian healthcare context.
- To identify potential challenges and strategies for equitable access to CAR T-cell therapy in Canada.
Main Methods:
- Review of recent clinical evidence for BCMA-targeting CAR T-cell therapies (Ide-cel and Cilta-cel).
- Analysis of clinical and logistical considerations for CAR T-cell therapy implementation.
- Discussion of potential challenges in Canadian access and management.
Main Results:
- Two BCMA-targeting CAR T-cell therapies (Ide-cel, Cilta-cel) show unprecedented efficacy in RRMM.
- These therapies have significant clinical and logistical limitations.
- CAR T-cell therapy is anticipated for approval in Canada soon.
Conclusions:
- CAR T-cell therapy represents a significant advancement for RRMM treatment.
- Equitable access and management strategies are essential for Canadian MM patients.
- Community providers and specialized programs must collaborate for long-term patient care, including managing side effects like infections and neurotoxicity.
